The Board

Alan Hulme
Alan Hulme
Chairman

Alan Hulme was appointed as Chairman of the Board in April 2010.

In addition to his Chairmanship of Oncopeptides, Alan works across Europe with other development stage client companies in the life sciences sector, providing corporate development consultancy services from his base in London.

Previous positions Alan has held have included various senior management positions in a number of US listed companies in the life sciences sector as well as two European companies, one of which was a venture backed start-up he co-founded

He has been located for extensive periods in Asia, the US and with assignments in Europe including the UK, Germany, France and Norway.

Alan holds a Fellowship of the Institute of Biomedical Sciences (UK).

Born: 1951
Board Committees: Chairman of the Remuneration Committee and member of the Nomination Committee
Holdings in Oncopeptides: 322,393 Shares, 95 Share Options*
Other current positions: Director of Oncopeptides Incentive AB, Techgen Corporate Development Ltd and Techgen International Ltd.

Non-independent in relation to the Company and its senior management, but independent in relation to major shareholders. Owner and Director of TechGen Corporate Development Limited which has entered into a consulting agreement with Oncopeptides AB.

Jonas Brambeck
Jonas Brambeck
PhD, Board member

Jonas Brambeck was appointed to the board of Oncopeptides in 2008.

In addition to being a board member of Oncopeptides, Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB, Cardoz AB and Nuevolution AS.

He has previously held positions at a number of life sciences businesses including AstraZeneca, Bruker Instruments and Nobel.

Jonas holds a PhD in organic chemistry from The Royal Institute of Technology in Stockholm.

Born: 1958
Board Committees: Chairman of the Audit Committee and Member of the Remuneration Committee
Holdings in Oncopeptides: Nil
Other current positions: Athera Biotechnologies AB, CMC Contrast AB, OxThera AB and OxThera Intellectual Property AB.

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Employee of Industrifonden Foundation (Stiftelsen Industrifonden).

Johan Christenson
Johan Christenson
MD, PhD, Board member

Johan Christenson was appointed to the board of Oncopeptides in 2012.

In addition to being a board member for Oncopeptides, Johan is a partner at HealthCap, a life sciences venture capital business.

Johan’s previous positions include supervising the health care portfolio at SEB Företagsinvest (the venture capital arm of SEB, a leading Swedish financial institution), as well as roles with life sciences businesses including Odlander Fredrikson SA and AstraZeneca. In addition, he held the position of Assistant Dean at the Karolinska Institute Graduate School for two years where he also served as a lecturer in neuroscience. Johan also has four years clinical specialist training in paediatrics and paediatric neurology and is the author of 17 scientific articles.

Johan holds a PhD in basic neuroscience from the Karolinska Institute in Stockholm.

Born: 1958
Board Committees: Member of the Audit Committee
Holdings in Oncopeptides: Nil
Other current positions: Chairman of Aprea Personal AB. Director of Ancilla AB, Aprea AB, Glionova AB, HealthCap Aero Holdings GP AB, Health-Cap Annex Fund I-II Bis GP AB, HealthCap Annex Fund I-II GP AB, HealthCap Holdings GP AB, HealthCap Orx Holdings GP AB, HealthCap 1999 GP AB, HealthCap III Sidefund GP AB, Health-Cap IV GP AB, Ibid AB, Trimb Holding AB, Nexstrim OY and Targovax ASA.

Independent in relation to the Company and its senior management, but not in relation to major shareholders where a number of Directorships are held within the HealthCap Group.

Luigi Costa
Luigi Costa
Board member

Luigi Costa was appointed to the board of Oncopeptides in 2016

Luigi has over 20 years of experience in the international pharmaceutical and biotech industries.

In addition to being a board member of Oncopeptide, Luigi is the CEO of Nordic Nanovector ASA, a public biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology.

Luigi’s previous positions include Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals where he led the company’s international organization and the prelaunch and launch of its multiple myeloma drug, Kyprolis® in markets outside the USA.

Prior to joining Onyx Pharmaceuticals, Luigi held several leadership positions with Amgen, including Head of International Oncology Fanchise, General Manager of Amgen Italy and President of Amgen France, the company’s largest market outside the USA.

He has also held various leadership positions with Eli Lilly both in Europe and America.

Luigi holds a BSc in Business Administration from the University of Parma and an MBA from Bocconi Business School in Milan.

Born: 1965
Board Committees: Member of the Audit Committee
Holdings in Oncopeptides: 49 Share Options*
Other current positions: CEO Nordic Nanovector ASA.

Independent in relation to the Company, its senior management and major shareholders.

Cecilia Daun Wennborg
Cecilia Daun Wennborg
Board member

Cecilia Daun Wennborg was appointed to the board of Oncopeptides in 2017.

Cecilia has 14 years of experience from board positions in listed companies. 20 years of experience from operational positions in the insurance, bank and care and healthcare sectors, inter alia as CFO and CEO of Skandia Link, head of Skandia Sverige, CFO of Carema Vård & Omsorg AB and Ambea AB, CEO of Carema Vård & Omsorg AB and deputy CEO of Ambea AB.

She was also ordinary member and chairman of the board of directors in Randstad AB (previously Proffice Aktiebolag), board member in Carnegie Fonder AB, Eniro AB, Ikano Bank AB (publ), Aktiebolaget Svensk Bilprovning and Kvinvest AB.

Cecilia holds a MSc in Business and Economics from Stockholm University.

Born: 1963
Holdings in Oncopeptides: 2,000 shares
Other current assignments: Member of the board of directors in Getinge AB, Bravida Holding AB, ICA Gruppen AB, Loomis AB, Atvexa AB, Insamlingsstiftelsen Oxfam Sverige, Sophiahemmet AB and the non-profit organisation Sophiahemmet, Hotel Diplomat AB and CDW Konsult AB. Deputy board member in Johan Wennborg Marketing AB.

Independent in relation to the Company and its management and in relation to major shareholders. Born in 1963.

Jarl Ulf Jungnelius
Jarl Ulf Jungnelius
MD, PhD, Board member

Jarl Ulf Jungnelius was appointed to the board of Oncopeptides in April 2011.

Ulf is a licensed medical practitioner and a specialist in a number of areas including oncology. He has published a number of scientific articles and has more than 25 years’ experience in leadership positions in both large academic and corporate institutions.

He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane).

Born: 1951
Holdings in Oncopeptides: 7,850 shares and 49 Share Options*
Other current positions: Director Biovica International AB, Isofol Medical AB, Monocl AB, Noxxon AG and HealthCom GmbH.

Independent in relation to the Company, its senior management and major shareholders.

Per Samuelsson
Per Samuelsson
MSc, Board member

Per Samuelsson was appointed to the board of Oncopeptides in 2012.

In addition to being a board member of Oncopeptides, Per is a partner at HealthCap, a life sciences venture capital business.

Per has over 15 years investment banking experience, mainly with Aros Securities based in Sweden. At Aros Securities he held a number of roles including being a Director in the corporate finance department where he specialized in merger transactions, initial public offerings and equity incentive programs. Per also held the role of Head of Research at Aros Securities.

Per holds an MSc in Engineering from the Institute of Technology in Linköping, Sweden.

Born: 1961
Board Committees: Member of the Remuneration Committee
Holdings in Oncopeptides: Nil
Other current positions: Director of Ancilla AB, Cantando AB, HealthCap AB, HealthCap Aero Holdings GP AB, HealthCap Annex Fund I-II Bis GP AB, HealthCap Annex Fund I-II GP AB, Health-Cap Holdings GP AB, HealthCap Orx Holdings GP AB, HealthCap 1999 GP AB, HealthCap III Sidefund GP AB, HealthCap IV GP AB, Kip Jansson Film 1 AB, NVC Holding AB, RSPR Incentive AB, RSPR Pharma AB, SwedenBIO Service AB, Nordic Nanovector ASA and Targovax ASA.

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Partner in HealthCap and holder of directorships in a number of companies within the HealthCap Group.

Olof Tydén
Olof Tydén
MD, PhD, Board member

Olof Tydén was appointed to the board of Oncopeptides in 2014.

In addition to his directorship with Oncopeptides, Olof is a Partner at Eureda, an international pharmaceutical consulting firm.

Olof has previously held positions as Medical Director at Leo Pharmaceuticals and Kabi-Vitrum (now Pfizer) and Programme Director at the Medical Products Agency in Sweden. Olaf was for six years Senior Regulatory Adviser at Hoffman-La Roche with responsibility for EU strategies, knowledge management and training. In 2000 he founded Eureda, a strategic regulatory consultancy. Olof has also served as an expert to the European Commission in Health Telematics and has been a member of the board of life sciences companies Bioxell SpA, Aprea AB, Cantargia AB and Ximmune AB.

Olof holds a PhD from Uppsala University and an associate professorship in obstetrics and gynaecology at Uppsala University.

Born: 1947
Holdings in Oncopeptides: 1,000 shares and 49 Share Options*
Other current positions: Director of Eureda AB. Alternate Director of Uppsala Medical Information AB.

Independent in relation to the Company, its senior management and major shareholders.

* Each option entitles the holder to acquire 900 new ordinary shares in the company, for more information please read under Corporate Governance – Remuneration.

Holdings in Oncopeptides AB as of February 28, 2017.